Conventional therapy for renal cell carcinoma using interleukin 2 (IL-2) has shown limited antitumor action. The purpose of our study was to investigate synergistic antitumor effects of IL-2 and Xiao-Chai-Hu-Tang (XCHT), and to elucidate the mechanisms of interaction between the two drugs against the murine renal cell carcinoma cell line, Renca, in vivo. The treatment was started 5 days after subcutaneous transplantation of Renca tumor. XCHT was given at a dose of 2.5g/kg daily for 30 days orally. IL-2 was given at a dose of 104 U/mouse by subcutaneous injection every other day 8 times. Combination of XCHT and IL-2 inhibited growth of the tumor and prolonged survival significantly as compared with the untreated mice. Increased cellular infiltration was observed in tumor tissue and the lungs of mice treated with XCHT alone and by combination of XCHT and IL-2, but there were no histological changes in the liver and kidney. Elevation of serum IL-6 was observed in tumor-bearing mice, but IL-6 was significantly suppressed by administration of XCHT. The results obtained suggest that combination of XCHT and IL-2 induces enhanced immunological reaction in specific organs and tissues, and IL-6 may have a role in the synergistic effect of these two agents. It was concluded that combination of XCHT and IL-2 is useful in the treatment of patients with renal cell carcinoma. (Keio J Med 46 (3): 132-137, September 1997) Key words: Xiao-Chai-Hu-Tang, interleuln 2, interleukin 6, Sino-Japanese medicine, renal cell carcinoma limited anti-tumor activity. Xiao-Chai-Hu-Tang (XCHT) is a traditional Chinese medicine composed of hot water extracts from 7 species of medical plants, Bupleuri Radix , Pinelliae Tuber, Scutellariae Radix, Zizyphi Fructus, Ginseng Radix ,
monal or chemotherapeutic agents so far tested has given an objective response rate greater than 15% by monotherapy. Interleukin 2 (IL-2), originally discovered as a T-cell growth factor, is a lymphokine produced by helper T lymphocytes.4 Treatment of tumor-bearing mice or patients with IL-2 alone, or combined with the adoptive transfer of lymphocytes activated by IL-2, has been shown to induce regression of the tumors. 1-7 However , conventional systemic IL-2 therapy has shown only transplanted. IL-6 concentrations were significantly lower in mice treated with XCHT alone than in untreated tumor-bearing mice. Serum IL-6 concen trations decreased by administration of IL-2 alone or combination of XCHT and IL-2 but there was no significant difference compared with untreated tumor bearing mice. Ratios of IL-6 concentration to tumor weights were then compared between each treatment group. The ratio in mice treated with XCHT alone was much lower than that in mice of other treatment groups (Table 3) . 
Histopathological analysis
Tumors, lungs, livers and kidneys were removed ten days after initiation of treatment and stained with hematoxylin-eosin. In the tumors of mice treated with XCHT, IL-2 or combination of XCHT and IL-2, en largement of nuclei and loosened intercellular con nection of tumor cells were observed. Marked cellular infiltration and scattered loss of tumor cells were observed in mice treated by combination of XCHT and IL-2 (Fig 2) . Cellular infiltration and alveolar wall thickening were observed in the lungs of mice treated with XCHT and in mice treated with the combination of XCHT and IL-2 (Fig 3) , but there were no histo logical changes in the liver and kidney (data not shown).
Discussion
Recently, it has been generally recognized that XCHT has a biological response modifier property. XCHT was shown to increase pokeweed mitogen induced production of IL-1p, IL-6 and granulocyte macrophage colony-stimulating factor (GM-CSF) by human peripheral blood mononuclear cells in vitro, 12 and oral administration of XCHT augments natural killer (NK) activity in mice. 13 We have expected that XCHT would have antitumor action in combination with IL-2 against renal cell carcinoma by activation of cytokine network of tumor-bearing animals or human. The present study has demonstrated that XCHT and IL-2 have a synergistic antitumor effect against Renca comitant use of XCHT and IFN, or IL-2, which is known to be an IFN-inducer, would enhance immunol ogical reaction in the specific organs or tissue, includ ing the lungs and tumor tissue. IL-6 was detected in the sera of mice bearing Renca tumor. This elevation of serum IL-6 is considered to be due to production of IL-6 by Renca tumor itself or by host immune mediating cells in the results of reaction with tumor cells and IL-6, originally identified as a B cell stimulatory factor (BSF-2),19 has been demon strated to have a variety of biological functions. IL-6 induces the terminal maturation of activated B cells to immunoglobulin-producing cells derived from T lym phocytes,' 9 stimulates acute phase protein synthesis in hepatocytes,20 acts on multipotential hematopoietic progenitors ,21 and was shown to be an autocrine growth factor for human multiple myeloma22 and renal cell carcinoma. 23 Blay et al24 reported elevation of serum IL-6 in 66 of 138 patients with advanced renal cell car cinoma, a poor prognosis in patients with elevated serum IL-6, and a poor response to IL-2 therapy in these patients. IL-6 is considered to have an important role in progression of renal cell carcinoma , con sequently, suppression of serum IL-6 in mice by administration of XCHT may be beneficial in the treat ment of Renca-bearing mice using IL-2.
Matsuura et al25 reported that intraperitoneal administration of Bupleuri Radix, Pinelliae Tuber , Scutellariae Radix, Ginseng Radix, Glycyrrhizae Radix and Zingiberis Rhizoma, which are included in XCHT as its constituents, induced serum IL-6 in mice, though , i n the present study, administration of XCHT reduced 
